The Safety of Oral Antifungal Treatments for Superficial Dermatophytosis and Onychomycosis: A Meta-analysis

American Journal of Medicine

Volumn 120, Issue 9, 2007, Pages

  Chang, Chia Hsuin ^a,b   Young Xu, Yinong ^c   Kurth, Tobias ^b,d   Orav, John E ^b   Chan, Arnold K ^b,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c EpiPatterns   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e i3 Drug Safety   (United States)

Author keywords

Adverse reactions; Antifungal agents; Dermatophytosis; Fluconazole; Harms; Itraconazole; Meta analysis; Onychomycosis; Safety; Systematic review; Terbinafine

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; PLACEBO; TERBINAFINE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED STUDY; DERMATOMYCOSIS; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; FEMALE; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; MORBIDITY; ONYCHOMYCOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; DERMATOMYCOSES; FLUCONAZOLE; HUMANS; ITRACONAZOLE; LIVER FUNCTION TESTS; MODELS, STATISTICAL; NAPHTHALENES; ONYCHOMYCOSIS; PULSE THERAPY, DRUG; RISK ASSESSMENT; TRANSAMINASES;

EID: 34548187423     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.03.021     Document Type: Article

References (26)

1. Vander Straten M.R., Hossain M.A., and Ghannoum M.A. Cutaneous infectious dermatophytosis, onychomycosis, and tinea versicolor. Infect Dis Clin N Am 17 (2001) 87-112
2. Elewsk B.E., and Charif M.A. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 133 (1997) 1172-1173
3. Ghannoum M.A., Hajjeh R.A., Scher R., et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 43 (2000) 641-648
4. Smith E.S., Fleischer A.B., Feldman S.T., and Williford P.M. Characteristics of office-based physician visits for cutaneous fungal infections: an analysis of 1990 to 1994 National Ambulatory Medical Care Survey Data. Cutis 69 (2002) 191-202
5. Gupta A.K., and Ryder J.E. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin 21 (2003) 469-479
6. Ajit C., Suvannasankha A., Zaeri N., and Munoz S.J. Terbinafine-associated hepatotoxicity. Am J Med Sci 325 (2003) 292-295
7. O'Sullivan D.P., Needham C.A., Bangs A., et al. Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br J Clin Pharmacol 42 (1996) 559-565
8. Hall M., Monka C., Krupp P., and O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 133 (1997) 1213-1219
9. Gupta A.K., Chwetzoff E., Del Rosso F., and Baran R. Hepatic safety of itraconazole. J Cutan Med Surg (2002) 210-213
10. Garcia-Rodriguez L.A., Castellsague A.D., Perez-Gutthann S., and Stricker B.H.C. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 48 (1999) 847-852
11. Alpsoy E., Yilmaz E., and Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 23 (1996) 259-262
12. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
13. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail?. An analysis of published data. Arch Dermatol 134 (1998) 1551-1554
14. Bell-Syer S.E.M., Hart R., Crawford F., et al. A systematic review of oral treatments for fungal infectious of the skin of the feet. J Dermatol Treat 12 (2001) 69-74
15. Cribier B.J., and Paul C. Long-term efficacy of antifungals in toenail onychomycosis: a critical review. Br J Dermatol 145 (2001) 446-452
16. Haugh M., Helou S., Boissel J.P., and Cribier B.J. Terbinafine in fungal infections of the nail: a meta-analysis of randomized clinical trials. Br J Dermatol 147 (2002) 118-121
17. Crawford F., Young P., Godfrey C., et al. Oral treatments for toenail onychomycosis. A systematic review. Arch Dermatol 138 (2002) 811-816
18. Bell-Syer S.E.M., Hart R., Crawford F., et al. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev 2 (2002) CD003584
19. Krob H.A., Fleischer A.B., D'Agostino R., and Feldman S.R. Terbinafine is more effective than itraconazole in treating toenail onychomycosis: results from a meta-analysis of randomized controlled trials. J Cutan Med Surg (2003) 306-311
20. Gupta A.K., Ryder J.E., and Johnson A.M. Cumulative meta-analysis of systematic antifungal agents for the treatment of onychomycosis. Br J Dermatol 150 (2004) 537-544
21. Chuang-Stein C. An application of the beta-binomial model to combine and monitor medical event rates in clinical trials. Drug Inf J 27 (1993) 515-523
22. Daniel W. Probability distribution. Biostatistics: A Foundation for Analysis in the Health Sciences. 7th ed. (1999), Wiley & Sons, New York 97
23. Agresti A., and Coull B. Approximate is better than 'exact' for interval estimation of binomial proportions. Am Stat 52 (1998) 119-126
24. Castellsague J., Garcia-Rodriguez L.A., Duque A., and Perez S. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatol 2 (2002) 14
25. Chitturi S., and Farrell G.C. Drug-induced liver disease. In: Schiff E.R., Sorell M.F., and Maddrey W.C. (Eds). Schiff's Diseases of the Liver. 9th ed. (2003), Lippincott, Williams & Wilkins, Philadelphia 1063
26. Ioannidis J.P.A., Evans S.J.W., Gotzsche P.C., et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141 (2004) 781-788